Literature DB >> 33314452

ADAURA: Mature Enough for Publication, Not for Prime Time.

Alfredo Addeo1, Giuseppe Luigi Banna2, Alex Friedlaender1.   

Abstract

Year:  2020        PMID： 33314452      PMCID： PMC8018310          DOI： 10.1002/onco.13637

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

1.  Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

Authors:  Chul Kim; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2015-12       Impact factor: 21.873

2.  Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer.

Authors:  Chong-Kin Liam
Journal:  Ann Transl Med       Date:  2019-02

3.  For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104).

Authors:  Kenichi Suda
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.

Authors:  Dongsheng Yue; Shidong Xu; Qun Wang; Xiaofei Li; Yi Shen; Heng Zhao; Chun Chen; Weimin Mao; Wei Liu; Junfeng Liu; Lanjun Zhang; Haitao Ma; Qiang Li; Yue Yang; Yongyu Liu; Haiquan Chen; Changli Wang
Journal:  Lancet Respir Med       Date:  2018-08-24       Impact factor: 30.700

5.  The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104).

Authors:  Song-Tao Xu; Jun-Jie Xi; Wen-Zhao Zhong; Wei-Min Mao; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Yong-Xing Zhang; Jia-Cheng Yin; Qun Wang; Yi-Long Wu
Journal:  J Thorac Oncol       Date:  2018-12-03       Impact factor: 15.609

6.  Diagnostic accuracy of MRI compared to CCT in patients with brain metastases.

Authors:  P D Schellinger; H M Meinck; A Thron
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

7.  Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Barbara Hermes; Jochen Schütte; Silke Cameron; Peter Hohenberger; Philipp J Jost; Salah-Eddin Al-Batran; Lars H Lindner; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Raija Kallio; Panu Jaakkola; Jouni Junnila; Thor Alvegård; Peter Reichardt
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

8.  SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Authors:  Nathan A Pennell; Joel W Neal; Jamie E Chaft; Christopher G Azzoli; Pasi A Jänne; Ramaswamy Govindan; Tracey L Evans; Daniel B Costa; Heather A Wakelee; Rebecca S Heist; Marc A Shapiro; Alona Muzikansky; Sudish Murthy; Michael Lanuti; Valerie W Rusch; Mark G Kris; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2018-11-16       Impact factor: 44.544

9.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Authors:  Yi-Long Wu; Masahiro Tsuboi; Jie He; Thomas John; Christian Grohe; Margarita Majem; Jonathan W Goldman; Konstantin Laktionov; Sang-We Kim; Terufumi Kato; Huu-Vinh Vu; Shun Lu; Kye-Young Lee; Charuwan Akewanlop; Chong-Jen Yu; Filippo de Marinis; Laura Bonanno; Manuel Domine; Frances A Shepherd; Lingmin Zeng; Rachel Hodge; Ajlan Atasoy; Yuri Rukazenkov; Roy S Herbst
Journal:  N Engl J Med       Date:  2020-09-19       Impact factor: 91.245
  9 in total
  5 in total

Review 1.  EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

Authors:  Xavier Cansouline; Béatrice Lipan; Damien Sizaret; Anne Tallet; Christophe Vandier; Delphine Carmier; Antoine Legras
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

2.  ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer.

Authors:  Ana Ortega-Franco; Shereen Rafee
Journal:  Oncol Ther       Date:  2022-03-16

3.  Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.

Authors:  Christopher A Lemmon; Emily C Zabor; Nathan A Pennell
Journal:  Oncologist       Date:  2022-05-06       Impact factor: 5.837

4.  From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer.

Authors:  Giuseppe Luigi Banna; Jarushka Naidoo; Alfredo Addeo
Journal:  Transl Lung Cancer Res       Date:  2022-07

Review 5.  Minimal residual disease in EGFR-mutant non-small-cell lung cancer.

Authors:  Nathan T Bain; Yang Wang; Surein Arulananda
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.